Rare disease pharmas could benefit from FDA guidance to...

2026-02-23 14:34:32 ET More on CRISPR Therapeutics, Intellia Therapeutics Crispr Therapeutics: Very High Risk, But Even Higher Potential Reward CRISPR Therapeutics AG (CRSP) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript Crispr: Emphasis Shifts To Cardiovascular Pipeline Amid Slow Casgevy Launch Insider trades: Merck, Intel, Micron among notable names Intellia rises as FDA lifts clinical hold on Regeneron-partnered gene editing drug Read the full article on Seeking Alpha For further details see: Rare disease pharmas could benefit from FDA guidance to accelerate development